China Railway Construction Corporation (01186) plans to issue corporate bonds not exceeding 3 billion yuan.

20:22 16/06/2026

China Railway Construction (01186) announced that China Railway Construction Corporation Limited will publicly issue technology innovation renewable corporate bonds (second phase) for professional investors in 2026, with a total amount not exceeding 30 billion yuan (including 30 billion yuan), divided into two types. The face interest rate inquiry range for type one is 1.40%-2.40%; the face interest rate inquiry range for type two is 1.90%-2.90%. The funds raised from this bond issuance, after deducting issuance expenses, will be used entirely for productive expenditures, including debt repayment, supplementing working capital, and other uses that comply with legal requirements.

China Railway Construction Corporation (01186) announced that China Railway Construction Corporation Limited will publicly issue technology innovation renewable corporate bonds (second tranche) for professional investors in 2026, with an issuance amount not exceeding 30 billion yuan (including 30 billion yuan) and divided into two tranches. The face interest rate inquiry range for the first tranche is 1.40%-2.40%; and for the second tranche is 1.90%-2.90%. The proceeds from this bond issuance, after deduction of issuance expenses, will be used entirely for production expenditures, including repayment of debt, supplementing working capital, and other uses in compliance with legal requirements.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-6914 Injection receives drug clinical trial approval notice.

Kafelaku Coffee (01869) plans to issue a maximum of 282 million shares for subscription at a discount of approximately 16.5%, raising a net amount of approximately 20.9 million Hong Kong dollars.

Jiangsu Hengrui Pharmaceuticals (01276): HRS-7525 tablets obtained drug clinical trial approval notification.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-6914 Injection receives drug clinical trial approval notice.

Kafelaku Coffee (01869) plans to issue a maximum of 282 million shares for subscription at a discount of approximately 16.5%, raising a net amount of approximately 20.9 million Hong Kong dollars.

Jiangsu Hengrui Pharmaceuticals (01276): HRS-7525 tablets obtained drug clinical trial approval notification.